Skip to main content

Table 3 Side effect score (out of 5) in the first 2 weeks and after 2 weeks of treatment with imepitoin in dogs treated with imepitoin with or without other anti-epileptic drugs

From: Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy

Side effect

All cases (n = 85)

(Median (25th–75th percentile)

Just imepitoin monotherapy cases (n = 56)

(Median (25th–75th percentile)

Initial 2 weeks

After 2 weeks

Initial 2 weeks

After 2 weeks

Eating more / would like to eat more

3 (0–4)

2 (0–4)

2 (0–4)

1 (0–4)

Gaining weight

0 (0–3)

0 (0–2)

0 (0–3)

0 (0–2)

Drinking more

2 (0–3)

1 (0–3)

1 (0–3)

1 (0–2.75)

Urinating more

1 (0–3)

0 (0–2.5)

0 (0–3)

0 (0–2)

Sleeping more than before

1 (0–3)

0 (0–2)

1 (0–3)

0 (0–2.75)

Wobbly / not coordinated when walking

0 (0–3)

0 (0–1)

0 (0–1.75)

0 (0–0)

Restlessness / pacing

0 (0–3)

0 (0–2)

0 (0–2)

0 (0–1)

Itchiness or skin rash

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–0)

Vomiting

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–0)

Diarrhoea

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–0)

Coughing

0 (0–0)

0 (0–0)

0 (0–0)

0 (0–0)

OVERALL SCORE (out of 55)

13 (4–19.5)

9 (1.5–15.5)

10 (2–16)

7 (1–13.75)

  1. Side effects were rated by owners on a six point scale from side effect not present (0), very mild (1), mild (2), moderate (3), severe (4), and very severe (5)